$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx

$lxrx Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000106282223000007 Filed on March 03, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$24.00K	$28.00K	$139.0K
YoY Change	-35.14%	100.0%	-53.36%
Cost Of Revenue	$0.00		$0.00
YoY Change
Gross Profit	$24.00K		$139.0K
YoY Change			-53.36%
Gross Profit Margin	100.0%		100.0%
Selling, General & Admin	$19.14M	$16.33M	$48.08M
YoY Change	125.42%	84.59%	48.67%
% of Gross Profit	79750.0%		34592.09%
Research & Development	$12.03M	$13.98M	$52.82M
YoY Change	-19.43%	-15.28%	-4.05%
% of Gross Profit	50108.33%		37997.12%
Depreciation & Amortization	$112.0K	$103.0K	$427.0K
YoY Change	2.75%	-8.04%	46.23%
% of Gross Profit	466.67%		307.19%
Operating Expenses	-$31.17M	$30.31M	$100.9M
YoY Change	-233.09%	19.58%	15.46%
Operating Profit	-$31.14M		-$100.8M
YoY Change	33.2%		15.7%
Interest Expense	$1.821M	-$1.103M	$2.780M
YoY Change	1555.45%	273.9%	246.63%
% of Operating Profit
Other Income/Expense, Net	$1.029M	$887.0K	$1.596M
YoY Change	7250.0%	6235.71%	1091.04%
Pretax Income	-$31.93M	-$30.49M	-$101.9M
YoY Change	36.03%	19.07%	16.16%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$31.93M	-$30.49M	-$101.9M
YoY Change	36.03%	19.07%	16.16%
Net Earnings / Revenue	-133058.33%	-108907.14%	-73341.01%
Basic Earnings Per Share	-$0.17		-$0.62
Diluted Earnings Per Share	-$0.17	-$0.16	-$0.62
COMMON SHARES
Basic Shares Outstanding	188.7M shares	188.7M shares	165.7M shares
Diluted Shares Outstanding	189.0M shares		165.7M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$105.9M	$138.4M	$138.4M
YoY Change	22.47%	59.5%	59.5%
Cash & Equivalents	$26.00M	$46.35M	$46.35M
Short-Term Investments	$79.94M	$92.01M	$92.01M
Other Short-Term Assets	$3.348M	$2.481M	$2.481M
YoY Change	76.96%	14.65%	14.65%
Inventory		$0.00
Prepaid Expenses
Receivables	$261.0K	$28.00K	$28.00K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$109.5M	$140.9M	$140.9M
YoY Change	23.88%	58.42%	58.42%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.207M	$2.071M	$4.371M
YoY Change	93.26%	76.11%	25.75%
Goodwill	$44.54M	$44.54M
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$6.420M	$6.819M	$4.519M
YoY Change	211.35%	200.53%	-14677.42%
Total Long-Term Assets	$53.17M	$53.43M	$53.43M
YoY Change	11.36%	11.35%	11.35%
TOTAL ASSETS
Total Short-Term Assets	$109.5M	$140.9M	$140.9M
Total Long-Term Assets	$53.17M	$53.43M	$53.43M
Total Assets	$162.7M	$194.3M	$194.3M
YoY Change	19.49%	41.92%	41.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$10.31M	$10.40M	$10.40M
YoY Change	10.62%	13.58%	13.58%
Accrued Expenses	$10.06M	$12.78M	$12.37M
YoY Change	4.97%	-1.5%	18.19%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$20.37M	$23.17M	$23.17M
YoY Change	7.75%	4.74%	4.74%
LONG-TERM LIABILITIES
Long-Term Debt	$48.85M	$48.58M	$48.58M
YoY Change	108.05%
Other Long-Term Liabilities	$5.454M	$5.424M	$5.424M
YoY Change	396.72%	355.8%	355.8%
Total Long-Term Liabilities	$54.30M	$5.424M	$54.00M
YoY Change	120.95%	355.8%	4438.07%
TOTAL LIABILITIES
Total Short-Term Liabilities	$20.37M	$23.17M	$23.17M
Total Long-Term Liabilities	$54.30M	$5.424M	$54.00M
Total Liabilities	$74.67M	$77.18M	$77.18M
YoY Change	71.73%	231.02%	231.02%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.622B	-$1.590B
YoY Change	7.31%	6.85%
Common Stock	$190.0K	$189.0K
YoY Change	26.67%	26.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$2.885M	$2.061M
YoY Change	39.98%	-72.59%
Treasury Stock Shares	868.0K shares	488.0K shares
Shareholders Equity	$88.05M	$117.1M	$117.1M
YoY Change
Total Liabilities & Shareholders Equity	$162.7M	$194.3M	$194.3M
YoY Change	19.49%	41.92%	41.92%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$31.93M	-$30.49M	-$101.9M
YoY Change	36.03%	19.07%	16.16%
Depreciation, Depletion And Amortization	$112.0K	$103.0K	$427.0K
YoY Change	2.75%	-8.04%	46.23%
Cash From Operating Activities	-$31.61M	-$21.57M	-$88.85M
YoY Change	34.98%	-5.52%	2.11%
INVESTING ACTIVITIES
Capital Expenditures	$248.0K	$1.246M	$1.326M
YoY Change	226.32%	-5517.39%	8.6%
Acquisitions
YoY Change
Other Investing Activities	$12.34M	$25.42M	-$69.75M
YoY Change	-384.88%	315.43%	-2194.03%
Cash From Investing Activities	$12.09M	$24.17M	-$71.08M
YoY Change	-374.34%	296.56%	-3468.63%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			-$93.34M
YoY Change			171.27%
Debt Paid & Issued, Net			-$48.87M
YoY Change			-517.68%
Cash From Financing Activities	-$824.0K	24.91M	$142.2M
YoY Change	-103.54%	-320.0%	526.22%
NET CHANGE
Cash From Operating Activities	-$31.61M	-21.57M	-$88.85M
Cash From Investing Activities	$12.09M	24.17M	-$71.08M
Cash From Financing Activities	-$824.0K	24.91M	$142.2M
Net Change In Cash	-$20.34M	27.51M	-$17.72M
YoY Change	347.61%	-198.07%	-71.51%
FREE CASH FLOW
Cash From Operating Activities	-$31.61M	-$21.57M	-$88.85M
Capital Expenditures	$248.0K	$1.246M	$1.326M
Free Cash Flow	-$31.86M	-$22.82M	-$90.18M
YoY Change	35.6%	0.04%	2.2%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	77381
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001062822
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2018Q3	us-gaap	Debt Instrument Term DebtInstrumentTerm	P2Y
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	000-30111
CY2022	dei	Entity Registrant Name EntityRegistrantName	Lexicon Pharmaceuticals, Inc.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	76-0474169
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	2445 Technology Forest Blvd., 11th Floor
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	The Woodlands,
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
CY2022	dei	City Area Code CityAreaCode	(281)
CY2022	dei	Local Phone Number LocalPhoneNumber	863-3000
CY2022	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2022	dei	Trading Symbol TradingSymbol	LXRX
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	134400000	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	188725743	shares
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1176000	usd
CY2022	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2022	dei	Auditor Location AuditorLocation	Houston, Texas
CY2022	dei	Auditor Firm AuditorFirmId	42
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	46345000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	64065000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	92012000	usd
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	22678000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	28000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	14000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2481000	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2164000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	140866000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	88921000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3984000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4853000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2071000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	44543000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	44543000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6819000	usd
CY2021Q4	us-gaap	Other Assets OtherAssets	2269000	usd
CY2022Q4	us-gaap	Assets Assets	194299000	usd
CY2021Q4	us-gaap	Assets Assets	136909000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10395000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9152000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12777000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12972000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	23172000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	22124000	usd
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	-48579000	usd
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5424000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1190000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	77175000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	23314000	usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	189000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	150000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1709144000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1608749000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1589720000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1487776000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-428000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-10000	usd
CY2022Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	488000	shares
CY2021Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	1165000	shares
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	2061000	usd
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	7518000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	117124000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	113595000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	194299000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	136909000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	usd
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	23404000	usd
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	0	usd
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	0	usd
CY2020	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	33000	usd
CY2022	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	139000	usd
CY2021	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	298000	usd
CY2020	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	558000	usd
CY2022	us-gaap	Revenues Revenues	139000	usd
CY2021	us-gaap	Revenues Revenues	298000	usd
CY2020	us-gaap	Revenues Revenues	23995000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	usd
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1929000	usd
CY2022	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	4253000	usd
CY2021	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	4284000	usd
CY2020	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	6376000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	52816000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	55046000	usd
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	153621000	usd
CY2022	lxrx	Stock Based Compensation Expense Associated With General And Administrative Expense StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense	7267000	usd
CY2021	lxrx	Stock Based Compensation Expense Associated With General And Administrative Expense StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense	6293000	usd
CY2020	lxrx	Stock Based Compensation Expense Associated With General And Administrative Expense StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense	6898000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	48083000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	32342000	usd
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	47230000	usd
CY2022	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	usd
CY2021	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	usd
CY2020	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	1600000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	100899000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	87388000	usd
CY2020	us-gaap	Operating Expenses OperatingExpenses	204380000	usd
CY2022	lxrx	Gain On Sale Of Non Financial Assets GainOnSaleOfNonFinancialAssets	0	usd
CY2021	lxrx	Gain On Sale Of Non Financial Assets GainOnSaleOfNonFinancialAssets	0	usd
CY2020	us-gaap	Gain Loss On Sale Of Proved Property GainLossOnSaleOfProvedProperty	132585000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-100760000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-87090000	usd
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-47800000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	1003000	usd
CY2022	us-gaap	Interest Expense InterestExpense	2780000	usd
CY2021	us-gaap	Interest Expense InterestExpense	802000	usd
CY2020	us-gaap	Interest Expense InterestExpense	14544000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1596000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	134000	usd
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2767000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-101944000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-87758000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-58574000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.62
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.60
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.53
CY2022	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	165733000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	145652000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	110841000	shares
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-418000	usd
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-4000	usd
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-90000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-102362000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-87762000	usd
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-58664000	usd
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	117101000	usd
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	13274000	usd
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	6963000	usd
CY2020	us-gaap	Sale Of Stock Consideration Received Per Transaction SaleOfStockConsiderationReceivedPerTransaction	63007000	usd
CY2020	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	15714000	usd
CY2020	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2000	usd
CY2020	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	1026000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-58574000	usd
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-90000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	156371000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10577000	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	35491000	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1593000	usd
CY2021	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	2675000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-87758000	usd
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-4000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	113595000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11520000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	0	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	94205000	usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	1030000	usd
CY2022	us-gaap	Stock Issued During Period Value Treasury Stock Reissued StockIssuedDuringPeriodValueTreasuryStockReissued	0	usd
CY2022	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	864000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-101944000	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-418000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	117124000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-101944000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-87758000	usd
CY2020	us-gaap	Profit Loss ProfitLoss	-58574000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	427000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	292000	usd
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2934000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	11520000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	10577000	usd
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	13274000	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	741000	usd
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	54000	usd
CY2020	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1013000	usd
CY2022	lxrx	Gain On Sale Of Non Financial Assets GainOnSaleOfNonFinancialAssets	0	usd
CY2021	lxrx	Gain On Sale Of Non Financial Assets GainOnSaleOfNonFinancialAssets	0	usd
CY2020	lxrx	Gain On Sale Of Non Financial Assets GainOnSaleOfNonFinancialAssets	132585000	usd
CY2022	us-gaap	Impairment Of Real Estate ImpairmentOfRealEstate	0	usd
CY2021	us-gaap	Impairment Of Real Estate ImpairmentOfRealEstate	0	usd
CY2020	us-gaap	Impairment Of Real Estate ImpairmentOfRealEstate	1600000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2020	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax	-1003000	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-3000	usd
CY2021	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-49000	usd
CY2020	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	707000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	14000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-381000	usd
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-53227000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	usd
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-345000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	316000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2885000	usd
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1948000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-656000	usd
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-661000	usd
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-424000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	76000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-14158000	usd
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-20969000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-88851000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-87017000	usd
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-142969000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1326000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1221000	usd
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	87000	usd
CY2022	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	0	usd
CY2021	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	0	usd
CY2020	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	160385000	usd
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
CY2020	us-gaap	Proceeds From Sale Of Buildings ProceedsFromSaleOfBuildings	11013000	usd
CY2022	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	133949000	usd
CY2021	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	34261000	usd
CY2020	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	58555000	usd
CY2022	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	64197000	usd
CY2021	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	37592000	usd
CY2020	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	268000000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-71078000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	2110000	usd
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	380756000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	94205000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	37084000	usd
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	69970000	usd
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	864000	usd
CY2021	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	2675000	usd
CY2020	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1026000	usd
CY2022	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	-48868000	usd
CY2021	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	11700000	usd
CY2020	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	216580000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	142209000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	22709000	usd
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-147636000	usd
CY2022	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-17720000	usd
CY2021	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-62198000	usd
CY2020	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	90151000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	64065000	usd
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	126263000	usd
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36112000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	46345000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	64065000	usd
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	126263000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	2289000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	799000	usd
CY2020	us-gaap	Interest Paid Net InterestPaidNet	17353000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	5206000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	1704000	usd
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	1030000	usd
CY2021	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	usd
CY2020	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	usd
CY2022Q4	us-gaap	Treasury Stock Carrying Basis TreasuryStockCarryingBasis	6321000	usd
CY2021	us-gaap	Stock Issued During Period Value Treasury Stock Reissued StockIssuedDuringPeriodValueTreasuryStockReissued	0	usd
CY2020	us-gaap	Stock Issued During Period Value Treasury Stock Reissued StockIssuedDuringPeriodValueTreasuryStockReissued	0	usd
CY2022	us-gaap	Business Exit Costs1 BusinessExitCosts1	1500000	usd
CY2021	us-gaap	Business Exit Costs1 BusinessExitCosts1	0	usd
CY2020	us-gaap	Business Exit Costs1 BusinessExitCosts1	0	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities	0	usd
CY2021Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities	0	usd
CY2020Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities	3437000	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	usd
CY2020	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	15714000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of financial statements in conformity with U. S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</span>
CY2022	lxrx	Disclosure On Geographic Areas Revenue From External Customers Attributed To Germany DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany	1
CY2021	lxrx	Disclosure On Geographic Areas Revenue From External Customers Attributed To Germany DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany	0.76
CY2021	lxrx	Disclosure On Geographic Areas Revenue From External Customers Attributed To Entitys Country Of Domicile Percent DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent	0.24
CY2020	lxrx	Disclosure On Geographic Areas Revenue From External Customers Attributed To Entitys Country Of Domicile Percent DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent	0.98
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2022	lxrx	Disclosure On Geographic Areas Revenue From External Customers Attributed To Germany DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany	1
CY2021	lxrx	Lxrx Biologicscustomerconcentration LXRXBiologicscustomerconcentration	0.76
CY2021	lxrx	Lxrx Diplomatcustomerconcentration LXRXDiplomatcustomerconcentration	0.24
CY2020	lxrx	Lxrx Biologicscustomerconcentration LXRXBiologicscustomerconcentration	0.65
CY2020	lxrx	Lxrx Diplomatcustomerconcentration LXRXDiplomatcustomerconcentration	0.22
CY2022Q4	lxrx	Accrued Research And Development Services Current AccruedResearchAndDevelopmentServicesCurrent	3252000	usd
CY2021Q4	lxrx	Accrued Research And Development Services Current AccruedResearchAndDevelopmentServicesCurrent	3669000	usd
CY2022Q4	lxrx	Accrued Compensation And Benefits Current AccruedCompensationAndBenefitsCurrent	7830000	usd
CY2021Q4	lxrx	Accrued Compensation And Benefits Current AccruedCompensationAndBenefitsCurrent	5711000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1291000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1089000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	404000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2503000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	12777000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	12972000	usd
CY2020	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	1600000	usd
CY2022	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
CY2021	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	21000000	usd
CY2022	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y3M18D
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	347100000	usd
CY2022Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	18418000	usd
CY2022Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2022Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	86000	usd
CY2022Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	18332000	usd
CY2021Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	26018000	usd
CY2021Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	5000	usd
CY2021Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	11000	usd
CY2021Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	26012000	usd
CY2022	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	46345000	usd
CY2022Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	92012000	usd
CY2022Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	138357000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	64065000	usd
CY2021Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	22678000	usd
CY2021Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	86743000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6055000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6029000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3984000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4853000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2071000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1176000	usd
CY2022	us-gaap	Noncash Or Part Noncash Divestiture Amount Of Consideration Received1 NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1	1300000	usd
CY2022	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	1300000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	251331000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	229427000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	29290000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	29290000	usd
CY2022Q4	lxrx	Deferred Tax Assets Tax Credit Carryforwards Orphan Drug DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug	24524000	usd
CY2021Q4	lxrx	Deferred Tax Assets Tax Credit Carryforwards Orphan Drug DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug	24524000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	33813000	usd
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	36770000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5445000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5163000	usd
CY2022Q4	lxrx	Deferred Tax Assets Section163j Lxrx DeferredTaxAssetsSection163j_LXRX	398000	usd
CY2021Q4	lxrx	Deferred Tax Assets Section163j Lxrx DeferredTaxAssetsSection163j_LXRX	148000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2255000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1308000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	347056000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	326630000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	1295000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	412000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1295000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	412000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	345761000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	326218000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.21
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-21408000	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-18429000	usd
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-12300000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-269000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	1627000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	851000	usd
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	1777000	usd
CY2022	lxrx	Write Off Of Tax Credits WriteOffOfTaxCredits	0	usd
CY2021	lxrx	Write Off Of Tax Credits WriteOffOfTaxCredits	0	usd
CY2020	lxrx	Write Off Of Tax Credits WriteOffOfTaxCredits	31053000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	19543000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	17210000	usd
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-20418000	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	238000	usd
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	368000	usd
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	157000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	1200000000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	86900000	usd
CY2022	lxrx	A2020 Federal Nol Increase A2020FederalNOLIncrease	104000000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	446300000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	19500000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2001Q3	lxrx	Coelacanth Goodwill CoelacanthGoodwill	25800000	usd
CY2001Q3	lxrx	Coelacanth Purchase Price CoelacanthPurchasePrice	36000000	usd
CY2010Q3	lxrx	Symphony Icon Goodwill SymphonyIconGoodwill	18700000	usd
CY2022Q4	lxrx	Oxford Loan Facility OxfordLoanFacility	150000000	usd
CY2022Q4	lxrx	Oxford Amendment Fee OxfordAmendmentFee	300000	usd
CY2022Q1	lxrx	Term Loan A TermLoanA	25000000	usd
CY2022Q4	lxrx	Term Loan B TermLoanB	25000000	usd
CY2022Q4	lxrx	Term Loan C TermLoanC	50000000	usd
CY2022Q4	lxrx	Term Loan D TermLoanD	50000000	usd
CY2025	lxrx	A2025 Oxford Principal Payment A A2025OxfordPrincipalPaymentA	8700000	usd
CY2026	lxrx	A2026 Oxford Principal Payments A2026OxfordPrincipalPayments	13000000	usd
CY2027	lxrx	A2027 Oxford Principal Payments A A2027OxfordPrincipalPaymentsA	4800000	usd
CY2025	lxrx	A2025 Oxford Principal Payments B A2025OxfordPrincipalPaymentsB	8700000	usd
CY2026	lxrx	A2026 Oxford Principal Payments B A2026OxfordPrincipalPaymentsB	13000000	usd
CY2027	lxrx	A2027 Oxford Principal Payments B A2027OxfordPrincipalPaymentsB	4800000	usd
CY2022Q4	lxrx	Term Loan Ab Warrant TermLoanABWarrant	0.0350
CY2022Q4	lxrx	Term Loan C Warrant TermLoanCWarrant	0.0175
CY2022Q4	lxrx	Term Loan D Warrant TermLoanDWarrant	0.00875
CY2022Q2	lxrx	Term Loan A Warrants Number TermLoanAWarrantsNumber	420673	shares
CY2022Q2	lxrx	Term Loan A Warrant Exercise Price TermLoanAWarrantExercisePrice	2.08
CY2022Q4	lxrx	Term Loan A Warrants Number TermLoanAWarrantsNumber	224128	shares
CY2022Q4	lxrx	Term Loan A Warrant Exercise Price TermLoanAWarrantExercisePrice	1.95
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	700000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	700000	usd
CY2022Q4	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	300000	usd
CY2022Q4	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	300000	usd
CY2022Q4	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0790
CY2022Q4	us-gaap	Long Term Debt Percentage Bearing Fixed Interest Rate LongTermDebtPercentageBearingFixedInterestRate	0.0801
CY2022Q4	us-gaap	Subordinated Borrowing Interest Rate SubordinatedBorrowingInterestRate	0.1204
CY2022Q4	lxrx	Final Payment With No Extention FinalPaymentWithNoExtention	0.06	rate
CY2022Q4	lxrx	Final Payment With Extention FinalPaymentWithExtention	0.07	rate
CY2022Q4	lxrx	Term Loan A Final Payment TermLoanAFinalPayment	1500000	usd
CY2022Q4	lxrx	Term Loan A Net Cash Receipt TermLoanANetCashReceipt	24150000	usd
CY2022Q4	lxrx	Term Loan A Debt Issuance Costs TermLoanADebtIssuanceCosts	350000	usd
CY2022Q4	lxrx	Oxford Facility Fee OxfordFacilityFee	500000	usd
CY2022Q4	lxrx	Term Loan A Final Payment TermLoanAFinalPayment	1500000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	700000	usd
CY2022Q4	lxrx	Term Loan B Net Cash Receipt TermLoanBNetCashReceipt	24960000	usd
CY2022Q4	lxrx	Term Loan B Debt Discount TermLoanBDebtDiscount	40000.00	usd
CY2022Q4	lxrx	Term Loan A Final Payment TermLoanAFinalPayment	1500000	usd
CY2022Q4	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	300000	usd
CY2022Q4	lxrx	Term Loan A Debt Discount TermLoanADebtDiscount	4400000	usd
CY2022	us-gaap	Interest Expense Interest Bearing Liability InterestExpenseInterestBearingLiability	2800000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	48600000	usd
CY2014Q4	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	87500000	usd
CY2022Q4	lxrx	Convertible Debt Instrument Interest Rate Stated Percentage ConvertibleDebtInstrumentInterestRateStatedPercentage	0.0525
CY2022Q4	lxrx	Convertible Debt Instrument Interest Rate Stated Percentage ConvertibleDebtInstrumentInterestRateStatedPercentage	0.0525
CY2020	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	75800000	usd
CY2020	lxrx	A2020 Convertible Debt Exchange Percentage Of Principal A2020ConvertibleDebtExchangePercentageOfPrincipal	0.85
CY2020	lxrx	A2020 Convertible Debt Exchange Share Payment Total A2020ConvertibleDebtExchangeSharePaymentTotal	10368956	shares
CY2020	lxrx	Convertible Debt Exchange Total Cash Consideration ConvertibleDebtExchangeTotalCashConsideration	50000000	usd
CY2020	lxrx	A2020 Convertible Debt Exchange Accrued Interest A2020ConvertibleDebtExchangeAccruedInterest	1300000	usd
CY2020Q4	lxrx	Convertible Debt Exchange ConvertibleDebtExchange	9600000	usd
CY2021Q4	us-gaap	Convertible Debt ConvertibleDebt	11600000	usd
CY2018Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2018Q3	lxrx	Mortgage Debt Instrument Revere Lxrx MortgageDebtInstrument_Revere_LXRX	12900000	usd
CY2018Q3	us-gaap	Property Plant And Equipment Useful Life PropertyPlantAndEquipmentUsefulLife	P10Y
CY2018Q3	lxrx	Mortgage Debt Interest Rate Base Revere Lxrx MortgageDebtInterestRate_Base_Revere_LXRX	0.055
CY2018Q3	lxrx	Mortgage Debt Interest Rate Base Revere Lxrx MortgageDebtInterestRate_Base_Revere_LXRX	0.055
CY2018Q3	lxrx	Mortgage Debt Interest Rate Base Plus Revere Lxrx MortgageDebtInterestRateBasePlus_Revere_LXRX	0.075
CY2018Q3	lxrx	Mortgage Debt Interest Rate Base Plus Revere Lxrx MortgageDebtInterestRateBasePlus_Revere_LXRX	0.075
CY2018Q3	lxrx	Mortgage Debt Balloon Payment Lxrx MortgageDebtBalloonPayment_LXRX	10300000	usd
CY2018Q3	lxrx	Mortgage Debt Balloon Payment Lxrx MortgageDebtBalloonPayment_LXRX	10300000	usd
CY2017Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	150000000	usd
CY2022Q4	us-gaap	Debt Weighted Average Interest Rate DebtWeightedAverageInterestRate	0.09
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6800000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2300000	usd
CY2022Q4	us-gaap	Short Term Lease Commitment Amount ShortTermLeaseCommitmentAmount	1300000	usd
CY2022Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	5400000	usd
CY2021Q4	us-gaap	Short Term Lease Commitment Amount ShortTermLeaseCommitmentAmount	1100000	usd
CY2021Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	1200000	usd
CY2021	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1800000	usd
CY2022	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1700000	usd
CY2022	us-gaap	Payments For Rent PaymentsForRent	1100000	usd
CY2021	us-gaap	Payments For Rent PaymentsForRent	800000	usd
CY2022Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P9Y6M
CY2021Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y10M24D
CY2022Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.096
CY2021Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.090
CY2022Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	805000000	usd
CY2022Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	1378000000	usd
CY2022Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	1220000	usd
CY2022Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	865000	usd
CY2022Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	881000	usd
CY2022Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	5644000	usd
CY2022Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	10793000	usd
CY2022	lxrx	Interest On Lease Payments InterestOnLeasePayments	-4078000	usd
CY2022Q4	lxrx	Present Value Of Future Lease Payments PresentValueOfFutureLeasePayments	6715000	usd
CY2022Q4	us-gaap	Short Term Lease Commitment Amount ShortTermLeaseCommitmentAmount	1291000	usd
CY2022Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	5424000	usd
CY2022	lxrx	Stock Option Exercise Price As Percent Of Value Of Common Stock StockOptionExercisePriceAsPercentOfValueOfCommonStock	1
CY2022Q4	lxrx	Total Shares That May Be Issued Equity Incentive Plan TotalSharesThatMayBeIssuedEquityIncentivePlan	30000000	shares
CY2022Q4	lxrx	Options Outstanding Equity Incentive Plan OptionsOutstandingEquityIncentivePlan	11847723	shares
CY2022Q4	lxrx	Restricted Stock Units Outstanding Equity Incentive Plan RestrictedStockUnitsOutstandingEquityIncentivePlan	2559306	shares
CY2022Q4	lxrx	Stock Options Exercised Equity Incentive Plan StockOptionsExercisedEquityIncentivePlan	2285702	shares
CY2022Q4	lxrx	Shares Issued Pursuant To Restricted Stock Units Equity Incentive Plan SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan	5294942	shares
CY2022Q4	lxrx	Shares Issued Pursuant To Stock Bonus Awards Equity Incentive Plan SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan	113940	shares
CY2022Q4	lxrx	Totalvalueofsharesbynonemployeeinayear Totalvalueofsharesbynonemployeeinayear	500000	usd
CY2022Q4	lxrx	Total Shares That May Be Issued Non Employee Directors Equity Incentive Plan TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan	1200000	shares
CY2022Q4	lxrx	Options Outstanding Non Employee Directors Equity Incentive Plan OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan	501224	shares
CY2022Q4	lxrx	Stock Options Exercised Non Employee Directors Equity Incentive Plan StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan	0	shares
CY2022Q4	lxrx	Restricted Stock Units Outstanding Non Employee Directors Equity Incentive Plan RestrictedStockUnitsOutstandingNonEmployeeDirectorsEquityIncentivePlan	74416	shares
CY2022Q4	lxrx	Shares Issued Pursuant To Restricted Stock Awards Non Employee Directors Equity Incentive Plan SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan	248232	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.30
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.85
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.35
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	usd
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y2M12D
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y3M18D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	100000	usd
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	2900000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	8700000	usd
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	3200000	usd
CY2022	lxrx	Share Based Compensation Arrangement By Share Based Payment Award Stock Bonus And Restricted Stock Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod	74416	shares
CY2021	lxrx	Share Based Compensation Arrangement By Share Based Payment Award Stock Bonus And Restricted Stock Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod	32192	shares
CY2020	lxrx	Share Based Compensation Arrangement By Share Based Payment Award Stock Bonus And Restricted Stock Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod	85104	shares
CY2022	lxrx	Sharebased Compensation Arrangementby Sharebased Payment Award Stock Bonusand Restricted Stockto Consultants Grantsin Period Weighted Average Grant Date Fair Value SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue	1.77
CY2021	lxrx	Sharebased Compensation Arrangementby Sharebased Payment Award Stock Bonusand Restricted Stockto Consultants Grantsin Period Weighted Average Grant Date Fair Value SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue	5.04
CY2020	lxrx	Sharebased Compensation Arrangementby Sharebased Payment Award Stock Bonusand Restricted Stockto Consultants Grantsin Period Weighted Average Grant Date Fair Value SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue	1.86
CY2022Q4	us-gaap	Treasury Stock Preferred Value TreasuryStockPreferredValue	6300000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	15096609	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	8160575	shares
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	700000	usd
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	400000	usd
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	900000	usd
CY2022	lxrx	Defined Contribution Plan Requisite Service Period DefinedContributionPlanRequisiteServicePeriod	P4Y
CY2020Q4	lxrx	Final Consideration Including Amounts Released To Settle FinalConsiderationIncludingAmountsReleasedToSettle	160000000	usd
CY2020	lxrx	Gain On Sale Of Non Financial Assets GainOnSaleOfNonFinancialAssets	132600000	usd
CY2020	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-12200000	usd
CY2020	us-gaap	Severance Costs1 SeveranceCosts1	5500000	usd
CY2020	lxrx	Ipsen Revenue Recognized IpsenRevenueRecognized	300000	usd
CY2020	lxrx	Ipsenproductsales Ipsenproductsales	1300000	usd
CY2020	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	20312500	shares
CY2020Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	3.20
CY2020Q4	lxrx	Proceeds From December2020 Common Stock Offering ProceedsFromDecember2020CommonStockOffering	63000000	usd
CY2020	lxrx	Commissions From December2020 Common Stock Offering CommissionsFromDecember2020CommonStockOffering	1800000	usd
CY2020	lxrx	Offering Expenses From December20 Common Stock Offering OfferingExpensesFromDecember20CommonStockOffering	200000	usd
CY2022	lxrx	Atm Offering2020 Total ATMOffering2020Total	50000000	usd
CY2020	lxrx	Shares Sold In Nov2020 Atm Offering SharesSoldInNov2020ATMOffering	3709233	shares
CY2020	lxrx	Share Price In November20 Atm Offering SharePriceInNovember20ATMOffering	1.992	usd
CY2020	lxrx	Proceeds From Nov2020 Atm Offering ProceedsFromNov2020ATMOffering	7000000	usd
CY2021	lxrx	Shares Sold In January2021 Atm Offering SharesSoldInJanuary2021ATMOffering	2000000	shares
CY2021	lxrx	Share Price In January2021 Atm Offering SharePriceInJanuary2021ATMOffering	8.463	shares
CY2021	lxrx	Proceeds From January2021 Atm Offering ProceedsFromJanuary2021ATMOffering	16400000	usd
CY2021	lxrx	Shares Sold In September2021 Atm Offering SharesSoldInSeptember2021ATMOffering	4176953	usd
CY2021	lxrx	Share Price In September2021 Atm Offering SharePriceInSeptember2021ATMOffering	4.732	usd
CY2021	lxrx	Proceeds From September2021 Atm Offering ProceedsFromSeptember2021ATMOffering	19100000	usd
CY2022	lxrx	Shares Sold In July2022 Offering SharesSoldInJuly2022Offering	39100000	shares
CY2022	lxrx	Share Price In July2022 Offering SharePriceInJuly2022Offering	2.50	usd
CY2022	lxrx	Proceeds From July2022 Offering ProceedsFromJuly2022Offering	94200000	usd

Files In Submission

Name	View Source	Status
lxrx-20221231_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
lxrx-20221231_cal.xml	Edgar Link	unprocessable
0001062822-23-000007-index-headers.html	Edgar Link	pending
0001062822-23-000007-index.html	Edgar Link	pending
0001062822-23-000007.txt	Edgar Link	pending
0001062822-23-000007-xbrl.zip	Edgar Link	pending
exh1010officerrestrictedst.htm	Edgar Link	pending
exh231ernstyoungconsent2022.htm	Edgar Link	pending
exh311certificationofprinc.htm	Edgar Link	pending
exh312certificationofprinc.htm	Edgar Link	pending
exh321certificationofprinc.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
lxrx-20221231.htm	Edgar Link	pending
lxrx-20221231.xsd	Edgar Link	pending
lxrx-20221231_g1.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
lxrx-20221231_pre.xml	Edgar Link	unprocessable
lxrx-20221231_lab.xml	Edgar Link	unprocessable
lxrx-20221231_htm.xml	Edgar Link	completed
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx

2023 Q1 Form 10-K Financial Statement

#000106282223000007 Filed on March 03, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LXRX LEXICON PHARMACEUTICALS, INC. Stock $lxrx

2023 Q1 Form 10-K Financial Statement

#000106282223000007 Filed on March 03, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx